Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has shared an update.
PYC Therapeutics Limited announced progress in its ~$146 million Entitlement Offer, having secured ~$133 million so far, which extends its cash runway to over $200 million. However, the underwriter for the remaining ~$13 million has requested an extension due to liquidity issues, prompting PYC to seek payment guarantees and a bond to mitigate potential risks, which could impact the company’s financial stability and stakeholder confidence.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company specializing in RNA therapies aimed at treating genetic diseases with no available treatment options. The company leverages its proprietary drug delivery platform to enhance the effectiveness of precision medicines, focusing on monogenic diseases which have a higher likelihood of success in clinical development.
YTD Price Performance: -21.76%
Average Trading Volume: 525,546
Technical Sentiment Signal: Buy
Current Market Cap: A$600.5M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.